Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Psychedelic renaissance stories

Oct 14, 2026

Compass Pathways CEO says company will 'go slow before we go fast' ahead of FDA submission

Compass Pathways CEO Kabir Nath stated the psychedelics company will take a measured approach as it prepares to complete submission of its psychedelic therapy for FDA regulatory review this quarter. The announcement comes as the company joins mental health organizations to mark the first U.S. Treatment-Resistant Depression Awareness Day.

Oct 14, 2026·3 sources
00
Sep 18, 2026

Compass Pathways prepares psychedelic drug launch following J&J's ketamine strategy

Compass Pathways executives revealed plans to model their upcoming psychedelic treatment launch after Johnson & Johnson's strategy for Spravato, the ketamine nasal spray, as the FDA considers approval. The move comes as psychedelic therapeutics face a critical juncture following Lykos' failed MDMA therapy approval in 2024.

Sep 18, 2026·2 sources
00
Sep 9, 2026

FDA suggests regulatory flexibility for assessing psychedelic therapies

The FDA indicated openness to innovative approaches for studying psychedelic therapies, including the use of comparators other than placebo, signaling potential regulatory accommodation for this emerging treatment class.

Sep 9, 2026·2 sources
00
Aug 5, 2026

Scientists Advance Understanding of Psychedelic Mechanisms Through New Research Tools and Theories

Researchers have developed engineered mouse models for studying psychedelic drug actions, proposed a new neurobiological theory called 'apical hypercontextualisation' to explain altered perception, and identified psychedelic candidates that may reduce side effects while maintaining therapeutic benefits.

Aug 5, 2026·3 sources
00
Jul 15, 2026

Eli Lilly nears deal to acquire psychedelic drugmaker AtaiBeckley

Eli Lilly is in advanced talks to acquire AtaiBeckley, a psychedelic medicine company, with a deal potentially announced this week. The acquisition underscores growing interest from major pharmaceutical companies in psychedelic therapies.

Jul 15, 2026·2 sources
00
Jun 22, 2026

Definium's LSD-Based Pill Reduces Depression Symptoms in Late-Stage Trial

Definium Therapeutics reported that a single dose of its LSD-based experimental pill significantly reduced symptoms of major depression in patients in a late-stage trial, sending shares higher. The data brings the drug closer to potential FDA approval.

Jun 22, 2026·2 sources
00

Top claims

  • ▪Compass Pathways expects COMP360 to be subject to an FDA risk evaluation and mitigation strategy (REMS) upon approval and is investing in provider training for drug administration.
  • ▪In Compass Pathways Phase 3 trials, roughly 40% of treatment-resistant depression patients experienced a clinically meaningful response after receiving two doses of COMP360 three weeks apart.
  • ▪The Treatment-Resistant Depression Awareness Day campaign is supported by the National Alliance on Mental Illness, Mental Health America, and the Depression and Bipolar Support Alliance.

Subtopics

Psychedelic clinical research & trials6Mental Health & Wellbeing4Psychedelic policy & regulation4Depression3Drug Approval and Clinical Trials3Drug Policy, Pricing & Approval3Pharma2Stress, Burnout & Well-being2Eli Lilly1Ketamine1LSD1MDMA1Mental health1Neuroplasticity1Psychedelic harm reduction1Psychedelics for depression1

Related timelines

Trump administration

161 stories

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Russia-Ukraine war

136 stories